

Special Issue

Advances in Cervical Cancer: From Pathogenesis to Therapy

Message from the Guest Editor

Cervical cancer is the fourth leading cause of cancer-related deaths in women. Multidisciplinary treatments such as surgery (open or minimally invasive surgery), radiotherapy, molecular-targeted drugs, and immune checkpoint inhibitors are in clinical use and at various stages of preclinical and clinical development. MIS, in particular, is the preferred approach; however, recent data on cervical cancer surgery (LACC trial) require a thorough reassessment. Papers focusing on histopathology examination techniques, validation of diagnostic tools, the development of innovative materials and therapies, gene therapy, and descriptions of new surgical approaches are also welcome.

Guest Editor

Dr. Eiji Kondo

Department of Obstetrics and Gynecology, Mie University School of Medicine, Tsu 514-8507, Mie, Japan

Deadline for manuscript submissions

closed (30 September 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/149779

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)